Source-grounded facts extracted from BIOXYTRAN, INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
BIOXYTRAN, INC: Filed Certificate of Amendment to the Certificate of Designation of Convertible Preferred Stock, effective upon filing (effective 2026-02-18).
“In connection with the amendment described above, the Company filed a Certificate of Amendment to the Certificate of Designation of Convertible Preferred Stock with the Nevada Secretary of State on February 18, 2026, which became effective upon filing.”
BIOXYTRAN, INC entered into Distribution Agreement with Khoury Medical LTD (effective 2026-02-10).
“On February 10, 2026, Bioxytran entered into a commercial Distribution Agreement, attached hereto as Exhibit 10.90, with Khoury Medical LTD”
BIOXYTRAN, INC engaged Fruci & Associates II, PLLC as its auditor.
“the Company engaged Fruci & Associates II, PLLC ("Fruci"), PCAOB ID # 05525, as their successor auditor in order to re-audit the Financial Statements for the years ended December 31, 2023 and 2022.”
BIOXYTRAN, INC engaged Fruci & Associates II, PLLC as its auditor.
“On May 7, 2024, Bioxytran, Inc. (the “Company”) dismissed BF Borgers CPA PC (“BF Borgers”) as its independent public accountants and appointed Fruci & Associates II, PLLC (PCAOB #5525) (“Fruci”) as its new independent accountants.”
BIOXYTRAN, INC dismissed BF Borgers CPA PC as its auditor.
“On May 7, 2024, Bioxytran, Inc. (the “Company”) dismissed BF Borgers CPA PC (“BF Borgers”) as its independent public accountants and appointed Fruci & Associates II, PLLC (PCAOB #5525) (“Fruci”) as its new independent accountants.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.